BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38003662)

  • 21. Clinically Defined Mutations in
    Duan S; Sheriff S; Elvis-Offiah UB; Witten BL; Sawyer TW; Sundaresan S; Cierpicki T; Grembecka J; Merchant JL
    Cancer Res Commun; 2023 Jul; 3(7):1318-1334. PubMed ID: 37492626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of an atypical BCR::ABL1 fusion in a patient with secondary B-cell acute lymphoblastic leukemia/lymphoma following multiple myeloma treatment.
    Miller K; Webster J; Imus P; Ament C; Hardy M; Zou YS
    Cancer Genet; 2023 Jun; 274-275():30-32. PubMed ID: 36966724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia.
    Klairmont MM; Zhou Y; Cheng C; Pui CH; Jeha S; Gruber TA; Liu Y; Inaba H; Choi JK
    Mod Pathol; 2021 Nov; 34(11):2050-2054. PubMed ID: 34148065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion.
    Tretti Parenzan C; Molin AD; Longo G; Gaffo E; Buratin A; Cani A; Boldrin E; Serafin V; Guglielmelli P; Vannucchi AM; Cazzaniga G; Biondi A; Locatelli F; Meyer LH; Buldini B; Te Kronnie G; Bresolin S; Bortoluzzi S
    Blood Adv; 2024 Mar; 8(5):1305-1319. PubMed ID: 38029383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia and is distinctly low in KMT2A-rearranged cases.
    Collins K; Cardinali JL; Mnayer LO; DiGiuseppe JA
    Cytometry B Clin Cytom; 2021 Mar; 100(2):243-248. PubMed ID: 31894899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
    Tomoyasu C; Imamura T; Tomii T; Yano M; Asai D; Goto H; Shimada A; Sanada M; Iwamoto S; Takita J; Minegishi M; Inukai T; Sugita K; Hosoi H
    Int J Hematol; 2018 Sep; 108(3):312-318. PubMed ID: 29786757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
    Zerkalenkova E; Lebedeva S; Kazakova A; Tsaur G; Starichkova Y; Timofeeva N; Soldatkina O; Aprelova E; Popov A; Ponomareva N; Baidun L; Meyer C; Novichkova G; Maschan M; Maschan A; Marschalek R; Olshanskaya Y
    Int J Lab Hematol; 2019 Apr; 41(2):287-292. PubMed ID: 30624859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation.
    Dreijerink KM; Varier RA; van Beekum O; Jeninga EH; Höppener JW; Lips CJ; Kummer JA; Kalkhoven E; Timmers HT
    Mol Cell Biol; 2009 Sep; 29(18):5060-9. PubMed ID: 19596783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
    Peterson JF; Baughn LB; Pearce KE; Williamson CM; Benevides Demasi JC; Olson RM; Goble TA; Meyer RG; Greipp PT; Ketterling RP
    Genes Chromosomes Cancer; 2018 Nov; 57(11):541-546. PubMed ID: 30203571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia.
    Cui W; Kong NR; Ma Y; Amin HM; Lai R; Chai L
    Mod Pathol; 2006 Dec; 19(12):1585-92. PubMed ID: 16998462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined BCL-2 and PI3K/AKT Pathway Inhibition in
    Holz C; Lange S; Sekora A; Knuebel G; Krohn S; Murua Escobar H; Junghanss C; Richter A
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic implications of menin inhibition in acute leukemias.
    Issa GC; Ravandi F; DiNardo CD; Jabbour E; Kantarjian HM; Andreeff M
    Leukemia; 2021 Sep; 35(9):2482-2495. PubMed ID: 34131281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
    Popov A; Tsaur G; Permikin Z; Henze G; Verzhbitskaya T; Plekhanova O; Nokhrina E; Valochnik A; Sibiryakov P; Zerkalenkova E; Olshanskaya Y; Gindina T; Movchan L; Shorikov E; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30204. PubMed ID: 36715125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
    Weisberg E; Chowdhury B; Meng C; Case AE; Ni W; Garg S; Sattler M; Azab AK; Sun J; Muz B; Sanchez D; Toure A; Stone RM; Galinsky I; Winer E; Gleim S; Gkountela S; Kedves A; Harrington E; Abrams T; Zoller T; Vaupel A; Manley P; Faller M; Chung B; Chen X; Busenhart P; Stephan C; Calkins K; Bonenfant D; Thoma CR; Forrester W; Griffin JD
    Blood Cancer J; 2022 Jul; 12(7):110. PubMed ID: 35853853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in
    Schneider P; Wander P; Arentsen-Peters STCJM; Vrenken KS; Rockx-Brouwer D; Adriaanse FRS; Hoeve V; Paassen I; Drost J; Pieters R; Stam RW
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.
    Matthijssens F; Sharma ND; Nysus M; Nickl CK; Kang H; Perez DR; Lintermans B; Van Loocke W; Roels J; Peirs S; Demoen L; Pieters T; Reunes L; Lammens T; De Moerloose B; Van Nieuwerburgh F; Deforce DL; Cheung LC; Kotecha RS; Risseeuw MD; Van Calenbergh S; Takarada T; Yoneda Y; van Delft FW; Lock RB; Merkley SD; Chigaev A; Sklar LA; Mullighan CG; Loh ML; Winter SS; Hunger SP; Goossens S; Castillo EF; Ornatowski W; Van Vlierberghe P; Matlawska-Wasowska K
    J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33555272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
    Blackburn PR; Smadbeck JB; Znoyko I; Webley MR; Pitel BA; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Lindsey KG; Schandl CA; Wolff DJ; Peterson JF
    Genes Chromosomes Cancer; 2020 Jul; 59(7):422-427. PubMed ID: 32196814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is acute lymphoblastic leukemia with mature B-cell phenotype and
    Hidalgo-Gómez G; Palacio-Garcia C; Gallur L; Blanco A; Tazón-Vega B; Saumell S; Martínez N; Murillo L; Murciano T; Velasco P; Bosch F; Diaz-Heredia C; Ortega M
    Leuk Lymphoma; 2021 Sep; 62(9):2202-2210. PubMed ID: 33827367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcription factor abnormalities in B-ALL leukemogenesis and treatment.
    Yin H; Wang J; Tan Y; Jiang M; Zhang H; Meng G
    Trends Cancer; 2023 Oct; 9(10):855-870. PubMed ID: 37407363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.